Actualizado Reviewed

Appendix B: Acronyms

 

General Terms
AcronymTerm
°Cdegrees Celsius
°Fdegrees Fahrenheit
% vvolume
25-OH-vitamin D25-hydroxy vitamin D
AAPAmerican Academy of Pediatrics 
ACTHadrenocorticotropic hormone
AEadverse effect
AHRadjusted hazard ratio
ALTalanine aminotransferase
ANCabsolute neutrophil count
appmobile application
ARTantiretroviral therapy
ARVantiretroviral
ASCVDatherosclerotic cardiovascular disease
ASTaspartate aminotransferase
AUCarea under the curve
AUC0-12harea under the curve from 0 to 12 hours postdose
AUC12h12-hour area under the curve
AUC24h24-hour area under the curve
AUCtauarea under the curve over the dosing interval
AVatrioventricular
BCRPbreast cancer resistance protein
BHIVABritish HIV Association
BMDbone mineral density
BMIbody mass index
BSAbody surface area
C0hpre-dose concentration
C12h concentration at 12 hours
C24hconcentration at 24 hours
CARchimeric antigen receptor
Cavgaverage plasma concentration
CBCcomplete blood count
CD4CD4 T lymphocyte
CD8CD8 T lymphocyte
CDCCenters for Disease Control and Prevention
CEPACCost-Effectiveness of Preventing AIDS Complications, a model
CIconfidence interval
CKcreatine kinase
Cmaxmaximum plasma concentration
Cminminimum plasma concentration
CMVcytomegalovirus
CNScentral nervous system
COMB-Rcognitive behavioral therapy and medication management algorithm 
Crcreatinine
CRAFFT Car, Relax, Alone, Forget, Friends, and Trouble
CrClcreatinine clearance
CTcontinuous therapy
Ctauconcentration at the end of a dosing interval
Ctroughtrough concentration
CTxC-telopeptide of type 1 collagen
CVcoefficients of variation
CVDcardiovascular disease
CYPcytochrome P450
CYPB26cytochrome P450 family 2 subfamily B member 6
DAIDSDivision of AIDS (NIAID)
DBSdried blood spot
DMdiabetes mellitus
DOTdirectly observed therapy
DRESSdrug reaction (or rash) with eosinophilia and systemic symptoms
DSGdelayed switch group
DTdispersible tablet
DXAdual energy x-ray absorptiometry
EBVEpstein-Barr virus
ECenteric-coated
EC50half maximal effective concentration
ECG electrocardiogram
ECMOextracorporeal membrane oxygenation 
EEGelectroencephalogram
eGFRestimated glomerular filtration rate
EMerythema multiforme or extensive metabolizers
FCTfilm-coated tablet
FDAU.S. Food and Drug Administration
FDCfixed-dose combination
FLPfasting lipid profile
FPGfasting plasma glucose
g/dLgrams per deciliter
G6PDglucose-6-phosphate dehydrogenase
GAgestational age
GFRglomerular filtration rate
GIgastrointestinal
GLSMgeometric least squares mean
GMgeometric mean
GMRgeometric mean ratio
gp120glycoprotein 120
HAheight age
HAVhepatitis A virus
HBcABHBV core antibody
HBsABHBV surface antibody
HBsAGHBV surface antigen
HBVhepatitis B virus
HCVhepatitis C virus
HDhigh dose
HDLhigh-density lipoprotein
HDL-Chigh-density lipoprotein cholesterol
Hgbhemoglobin
HgbA1cglycosylated hemoglobin
HHSU.S. Department of Health and Human Services
HIV RNA or HIV-1 RNAviral load
HLAhuman leukocyte antigen
HMG-CoA3-hydroxy-3-methylglutaryl coenzyme A
HRSAHealth Resources and Services Administration
HSRhypersensitivity reaction
HSVherpes simplex virus
IAS-USAInternational Antiviral Society-USA
IFPGimpaired fasting plasma glucose
IGTimpaired glucose tolerance
IMintramuscular
INSTIintegrase strand transfer inhibitor
IQinhibitory quotient
IQRinterquartile range
IRinsulin resistance
IRISimmune reconstitution inflammatory syndrome
ISGimmediate switch group
IUinternational units
IVintravenous
IVIGintravenous immune globulin
Lliter
LAIlong-acting injectable
LBWlow birth weight
LDLlow-density lipoprotein
LDL-Clow-density lipoprotein cholesterol
LFTliver function test
Log10the logarithm to the base 10
LSlipodystrophy syndrome
LVHleft ventricular hypertrophy
MCVmean cell volume
mDAARTmodified directly administered ART
MEMSmedication event monitoring system
N/Anot available or not applicable
NASBAnucleic acid sequence-based amplification
NATnucleic acid test
NHLBINational Heart, Lung, and Blood Institute
NIHNational Institutes of Health
nMnanometer
NNRTInon-nucleoside reverse transcriptase inhibitor
NRTInucleoside reverse transcriptase inhibitor
NTDneural tube defect
OARACOffice of AIDS Research Advisory Council
OATorganic anion transporter
OATPorganic anion transporter polypeptide
OBToptimized background therapy
OGTToral glucose tolerance test
OIopportunistic infection
ORodds ratio
PA-IC95protein-adjusted IC95
The Panelthe Panel on Antiretroviral Therapy and Medical Management of Children Living with HIV
PBMCperipheral blood mononuclear cell
PCPPneumocystis jirovecii pneumonia
PEPFARPresident's Emergency Plan for AIDS relief 
PCRpolymerase chain reaction
PEPpost-exposure prophylaxis
PGplasma glucose
P-gpP-glycoprotein
PHIVperinatally acquired HIV
PKpharmacokinetic
PIprotease inhibitor
POCpoint of care
PPIproton pump inhibitor
PrEPpre-exposure prophylaxis
pypatient years
QTccorrected QT
RCTrandomized controlled trial
RPGrandom plasma glucose
RRrelative risk
RT-PCRreverse transcription polymerase chain reaction
SAMsevere acute malnutrition
SBIRTScreening, Brief, Intervention, and Referral to Treatment 
SCTshort-cycle therapy
SDstandard deviation
SJSStevens-Johnson syndrome
SMslow metabolizers
SMRsexual maturity rating
SMSshort message service
SOCstandard of care
SQsubcutaneous
STIsexually transmitted infection
STRsingle-tablet regimen
T½half-life
TBtuberculosis
TBLHtotal body less head
TCtotal cholesterol
TDMtherapeutic drug monitoring
TENtoxic epidermal necrolysis
TGtriglyceride
TICtrauma-informed care
TMAtranscription-mediated amplification
Tmaxtime to reach maximum concentration
U=UUndetectable = Untransmittable
UGTuridine diphosphate glucuronosyltransferase
UGT1A and UGT1A1

uridine diphosphate (UDP)-glucuronosyltransferase family 1 member A complex or 

uridine diphosphate (UDP)-glucuronosyltransferase family 1 member A complex 1

ULNupper limit of normal
v/vvolume per volume
wweight
WHOWorld Health Organization

 

Appendix B: Acronyms

 

General Terms
AcronymTerm
°Cdegrees Celsius
°Fdegrees Fahrenheit
% vvolume
25-OH-vitamin D25-hydroxy vitamin D
AEadverse effect
AHRadjusted hazard ratio
ALTalanine aminotransferase
ANCabsolute neutrophil count
appmobile application
ARTantiretroviral therapy
ARVantiretroviral
ASCVDatherosclerotic cardiovascular disease
ASTaspartate aminotransferase
AUCarea under the curve
AUC0-12harea under the curve at 12 hours post-dose
AUC24harea under the curve at 24 hours post-dose
AUCtauarea under the curve
AVatrioventricular
BCRPbreast cancer resistance protein
BHIVABritish HIV Association
BMDbone mineral density
BMIbody mass index
BSAbody surface area
C0hpre-dose concentration
C12h concentration at 12 hours
C24hconcentration at 24 hours
CARchimeric antigen receptor
Cavgaverage plasma concentration
CBCcomplete blood count
CD4CD4 T lymphocyte
CDCCenters for Disease Control and Prevention
CIconfidence interval
CKcreatine kinase
Cmaxmaximum plasma concentration
Cminminimum plasma concentration
CMVcytomegalovirus
CNScentral nervous system
Crcreatinine
CrClcreatinine clearance
CTcontinuous therapy
Ctauconcentration at the end of a dosing interval
Ctroughtrough concentration
CTxC-telopeptide of type 1 collagen
CVcoefficients of variation
CVDIcardiovascular disease
CYPcytochrome P
CYPB26cytochrome P450 family 2 subfamily B member 6
DAIDSDivision of AIDS (NIAID)
DBSdried blood spot
dLdeciliter
DMdiabetes mellitus
DNAdeoxyribonucleic acid
DOTdirectly observed therapy
DRESSdrug reaction (or rash) with eosinophilia and systemic symptoms
DSGdelayed switch group
DSMBData Safety Monitoring Board
DTdispersible tablet
DXAdual energy x-ray absorptiometry
E2D2Every Dose, Every Day [Toolkit and App]
EBVEpstein-Barr virus
ECenteric-coated
EC50half maximal effective concentration
ECG electrocardiogram
EEGelectroencephalogram
eGFRestimated glomerular filtration rate
EMerythema multiforme or extensive metabolizers
FCTfilm-coated tablet
FDAFood and Drug Administration
FDCfixed-dose combination
fLfemtoliter
FLPfasting lipid profile
fmolfemtomole
FPGfasting plasma glucose
ggram
g/dLgrams per deciliter
G6PDglucose-6-phosphate dehydrogenase
GAgestational age
GFRglomerular filtration rate
GIgastrointestinal
GLSMgeometric least squares mean
GMgeometric mean
GMRgeometric mean ratio
gpglycoprotein
gp120glycoprotein 120
hhour
HAheight age
HAVhepatitis A virus
HBVhepatitis B virus
HCVhepatitis C virus
HDhigh dose
HDL-Chigh-density lipoprotein cholesterol
Hgbhemoglobin
HgbA1cglycosylated hemoglobin
HHSDepartment of Health and Human Services
HIV RNA or HIV-1 RNAviral load
HLAhuman leukocyte antigen
HRSAHealth Resources and Services Administration
HSRhypersensitivity reaction
HSVherpes simplex virus
IAS-USAInternational Antiviral Society-USA
IFPGimpaired fasting plasma glucose
IGTimpaired glucose tolerance
IMintramuscular
INSTIintegrase strand transfer inhibitor
IQinhibitory quotient
IQRinterquartile range
IRinsulin resistance
IRISimmune reconstitution inflammatory syndrome
ISGimmediate switch group
IUinternational units
IVintravenous
IVIGintravenous immune globulin
kgkilogram
Lliter
LAIlong-acting injectable
LBWlow birth weight
LDLlow-density lipoprotein
LDL-Clow-density lipoprotein cholesterol
LFTliver function test
Log10the logarithm to the base 10
LSlipodystrophy syndrome
LVHleft ventricular hypertrophy
m2square meter
mcg microgram
MCVmean cell volume
mDAARTmodified directly administered ART
MEMSMedication Event Monitoring System
mgmilligram
minminute
mLmilliliter
mmmillimeter
mm3cubic millimeter
mmolmillimole
N/Anot available or not applicable
NASBAnucleic acid sequence-based amplification
NATnucleic acid test
ngnanogram
NHLBINational Heart, Lung, and Blood Institute
NIHNational Institutes of Health
nMnanometer
NNRTInon-nucleoside reverse transcriptase inhibitor
NRTInucleoside reverse transcriptase inhibitor
NTDneural tube defect
OARACOffice of AIDS Research Advisory Council
OATorganic anion transporter
OATPorganic anion transporter polypeptide
OBToptimized background therapy
OGTToral glucose tolerance test
OIopportunistic infection
ozounce
PA-IC95protein-adjusted IC95
The Panelthe Panel on Antiretroviral Therapy and Medical Management of Children Living With HIV
PBMCperipheral blood mononuclear cell
PCPPneumocystis jirovecii pneumonia
PCRpolymerase chain reaction
PEPpost-exposure prophylaxis
PGplasma glucose
P-gpP-glycoprotein
PIprotease inhibitor
PKpharmacokinetic
POCpoint of care
PPIproton pump inhibitor
PrEPpre-exposure prophylaxis
PUFApolyunsaturated fatty acid
pypatient years
QTccorrected QT
RCTrandomized controlled trial
RNAribonucleic acid
RPGrandom plasma glucose
RRrelative risk
RT-PCRreverse transcription polymerase chain reaction
SAMsevere acute malnutrition
SCTshort-cycle therapy
SDstandard deviation
SJSStevens-Johnson syndrome
SMslow metabolizers
SMRsexual maturity rating
SMSshort message service
SOCstandard of care
SQsubcutaneous
STIsexually transmitted infection
STRsingle-tablet regimen
T½half-life
TBtuberculosis
TBLHtotal body less head
TCtotal cholesterol
TDMtherapeutic drug monitoring
TENtoxic epidermal necrolysis
TGtriglyceride
TMAtranscription-mediated amplification
Tmaxtime to reach maximum concentration
U=UUndetectable = Untransmittable
UGTuridine diphosphate glucuronosyltransferase
UGT1Auridine diphosphate (UDP)-glucuronosyltransferase family 1 member A complex
ULNupper limit of normal
v/vvolume per volume
wweight
WHOWorld Health Organization
XRextended release

 

Download Guidelines